1. Home
  2. NAZ vs IPHA Comparison

NAZ vs IPHA Comparison

Compare NAZ & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Arizona Quality Municipal Income Fund

NAZ

Nuveen Arizona Quality Municipal Income Fund

HOLD

Current Price

$12.92

Market Cap

171.0M

Sector

Finance

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.75

Market Cap

189.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NAZ
IPHA
Founded
1992
1999
Country
United States
France
Employees
N/A
163
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
171.0M
189.5M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
NAZ
IPHA
Price
$12.92
$1.75
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.75
AVG Volume (30 Days)
16.7K
17.6K
Earning Date
01-01-0001
03-26-2026
Dividend Yield
3.69%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$180.36
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.50
$1.18
52 Week High
$13.42
$2.63

Technical Indicators

Market Signals
Indicator
NAZ
IPHA
Relative Strength Index (RSI) 51.87 53.87
Support Level $11.81 $1.73
Resistance Level $13.00 $1.90
Average True Range (ATR) 0.26 0.07
MACD -0.06 -0.01
Stochastic Oscillator 48.45 57.42

Price Performance

Historical Comparison
NAZ
IPHA

About NAZ Nuveen Arizona Quality Municipal Income Fund

Nuveen Arizona Quality Municipal Income Fund is a closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: